Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Butcher

Showing results (251-260 of 275) with videos related to

Pageof 28
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|September 23, 1997
Novel HY peptide antigens presented by HLA-B27W A Simmons, S G Summerfield, D C Roopenian, et al.
Bioorganic & Medicinal Chemistry Letters|August 4, 2009
Synthesis and evaluation of novel tricyclic benzo[4.5]cyclohepta[1.2]pyridine derivatives as NMDA/NR2B antagonistsCharles J McIntyre, John A McCauley, Bohumil Bednar, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 2, 2010
Loss of T cell and B cell quiescence precedes the onset of microbial flora-dependent wasting disease and intestinal inflammation in Gimap5-deficient miceMichael J Barnes, Halil Aksoylar, Philippe Krebs, et al.
Journal of the American Chemical Society|March 15, 2008
Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A proteaseNigel J Liverton, M Katharine Holloway, John A McCauley, et al.
Journal of Medicinal Chemistry|January 26, 2007
Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonistNigel J Liverton, Rodney A Bednar, Bohumil Bednar, et al.
Journal of Medicinal Chemistry|December 16, 1997
Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)- 2, 3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamideH G Selnick, N J Liverton, J J Baldwin, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma ExposureMichael T Rudd, John A McCauley, John W Butcher, et al.
Critical Care Explorations|May 20, 2020
Key Components of ICU Recovery Programs: What Did Patients Report Provided Benefit?Joanne McPeake, Leanne M Boehm, Elizabeth Hibbert, et al.
American Journal of Critical Care : an Official Publication, American Association of Critical-Care Nurses|February 10, 2021
Benefits of Peer Support for Intensive Care Unit Survivors: Sharing Experiences, Care Debriefing, and AltruismJoanne McPeake, Theodore J Iwashyna, Leanne M Boehm, et al.
Journal of Medicinal Chemistry|February 19, 2010
Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitorJohn A McCauley, Charles J McIntyre, Michael T Rudd, et al.
Pageof 28

Showing results (251-260 of 275) with videos related to

Sort By:
Pageof 28
Journal of Immunology (Baltimore, Md. : 1950)|September 23, 1997
Novel HY peptide antigens presented by HLA-B27W A Simmons, S G Summerfield, D C Roopenian, et al.
Bioorganic & Medicinal Chemistry Letters|August 4, 2009
Synthesis and evaluation of novel tricyclic benzo[4.5]cyclohepta[1.2]pyridine derivatives as NMDA/NR2B antagonistsCharles J McIntyre, John A McCauley, Bohumil Bednar, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 2, 2010
Loss of T cell and B cell quiescence precedes the onset of microbial flora-dependent wasting disease and intestinal inflammation in Gimap5-deficient miceMichael J Barnes, Halil Aksoylar, Philippe Krebs, et al.
Journal of the American Chemical Society|March 15, 2008
Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A proteaseNigel J Liverton, M Katharine Holloway, John A McCauley, et al.
Journal of Medicinal Chemistry|January 26, 2007
Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonistNigel J Liverton, Rodney A Bednar, Bohumil Bednar, et al.
Journal of Medicinal Chemistry|December 16, 1997
Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)- 2, 3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamideH G Selnick, N J Liverton, J J Baldwin, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma ExposureMichael T Rudd, John A McCauley, John W Butcher, et al.
Critical Care Explorations|May 20, 2020
Key Components of ICU Recovery Programs: What Did Patients Report Provided Benefit?Joanne McPeake, Leanne M Boehm, Elizabeth Hibbert, et al.
American Journal of Critical Care : an Official Publication, American Association of Critical-Care Nurses|February 10, 2021
Benefits of Peer Support for Intensive Care Unit Survivors: Sharing Experiences, Care Debriefing, and AltruismJoanne McPeake, Theodore J Iwashyna, Leanne M Boehm, et al.
Journal of Medicinal Chemistry|February 19, 2010
Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitorJohn A McCauley, Charles J McIntyre, Michael T Rudd, et al.
Pageof 28